New long-acting insulin configurations are being developed and launched because the patent on Lantus is set to expire soon. In the United States the Lantus patent expires February 2015 and the drug’s patent expires in Europe in May 2015.
The U.S. Food and Drug Administration (FDA) has accepted for review Sanofi’s New Drug Application (NDA) for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), an investigational basal insulin. The acceptance of the NDA follows the acceptance of the marketing authorization dossier for Toujeo by the European Medicines Agency (EMA) for EU countries on May 27, 2014.
Lamb has always been one of my favorite meats but I only recently started putting it on the grill. A boneless leg of lamb can be laid out flat and cooks quite quickly on the grill. And the flavour is out of this world. If the lamb isn’t butterflied to an even thickness, simply use a sharp knife to cross-hatch in all over (on the inside) to allow it to lay more evenly.
In my blog post last week, I talked about how I’m hoping to transition to an insulin pump this summer. I know it will be a bit of an arduous process, but…
Given that new tools to detect hypoglycemia, such as continuous glucose monitors, are now available, lead the authors to issue a target of 7.5% A1C for the entire pediatric population. It is important to note that despite the new lower recommendation, a recent study showed that only 32% of the Type 1 pediatric population met the previous ADA targets for their age group.
Other recipes I am eager to try are Scallion Pancakes with Soy Ginger Sauce, Cake Brownies, Garlic-Cauliflower Breadsticks, and Matzo Ball Soup. The pictures and Kerwien’s commentary entice. For these and all the recipes, she suggests additions (frosting for the brownies!), side dishes, and substitutions.
Jacobson was involved in the most comprehensive long-term study of whether hypoglycemia adversely impacts brain function. As part of a team Jacobson studied the effects of improved blood sugar control on type 1 diabetic patients who were participants in The Diabetes Control and Complications Trial—or DCCT.
I feel like word “transition” has defined my existence for the past three or so years.
At first, it was the transition from high school to college.…
In a few days, our family is leaving on a trip halfway around and down toward the bottom of the world—my Mom is taking us on a safari in South Africa to…
The U.S. FDA approved Mannkind Corporation's Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin, to improve glycemic control in adults with diabetes mellitus. Afrezza is administered at the beginning of each meal, or within 20 minutes after starting a meal.